Click the Research Topic of Interest Below
Tap the topic of interest to collapse the information.
Cannabinoids in Treating Fibromyalgia, Rheumatoid Arthritis, and Osteoarthritis (California REsidents)
Exclusive Research Opportunity For California Residents
We are excited to share a new research opportunity with you!
Researchers from the University of Michigan are conducting a study on the efficacy of different cannabinoids in treating Fibromyalgia, Rheumatoid Arthritis, and Osteoarthritis and YOU have the opportunity to participate!
If you complete the study you may receive up to $500 in Amazon gift cards.
Learn more here!
The study sponsors are LEVEL and Overcome. Participants will receive a study product in the form of a tablet or capsule from one of the sponsors.
Each participant will be in the study for 12 weeks and able to do so from the comfort and safety of their home via their smartphone.
The study is limited and on a first come first serve basis. To learn more and find out if you are eligible to participate, please visit releaf.at/umpain
We are excited to share a new research opportunity with you!
Researchers from the University of Michigan are conducting a study on the efficacy of different cannabinoids in treating Fibromyalgia, Rheumatoid Arthritis, and Osteoarthritis and YOU have the opportunity to participate!
If you complete the study you may receive up to $500 in Amazon gift cards.
Learn more here!
The study sponsors are LEVEL and Overcome. Participants will receive a study product in the form of a tablet or capsule from one of the sponsors.
Each participant will be in the study for 12 weeks and able to do so from the comfort and safety of their home via their smartphone.
The study is limited and on a first come first serve basis. To learn more and find out if you are eligible to participate, please visit releaf.at/umpain
Dermatomyositis
Patients with dermatomyositis are invited to join a study opportunity to help advance research! If you are aged 18+ with dermatomyositis and you do not have chronic kidney disease, you could be part of the work that may help researchers understand more about the disease, and how to possibly treat it. Check your eligibility below...
Prescription Opioid Taper Support (POTS) and Medical Cannabis Study
Conducted By: Massachusetts General Hospital, Cambridge Health Alliance, MaineHealth
Location: At-home or in-person at one of three study sites in Massachusetts and Maine
Description: The POTS Study is investigating how medical cannabis and a six-month pain management training program can affect opioid use and pain. The goal of the study is to see whether medical cannabis and/or the pain management program might help people reduce their dose of opioid medications and better manage their pain.
The study will involve 3 components:
Who can participate: Adults ages 18-75 who use prescription opioid medications for chronic pain and do not regularly use cannabis
Contact: Call 617-643-4537 or email potsandmm@mgh.harvard.edu
Location: At-home or in-person at one of three study sites in Massachusetts and Maine
Description: The POTS Study is investigating how medical cannabis and a six-month pain management training program can affect opioid use and pain. The goal of the study is to see whether medical cannabis and/or the pain management program might help people reduce their dose of opioid medications and better manage their pain.
The study will involve 3 components:
- A weekly Prescription Opioid Taper Support (POTS) group, where you will work with trained clinicians to learn pain management skills and create an individualized opioid reduction plan to match your goals. Groups meet weekly for 26 weeks over Zoom.
- Daily surveys, where you will be asked to complete a short (1-2 minute) survey on your phone each day to help keep track of your pain levels, medications, and health.
- 8 study visits, which are completed over 6 months, and can be done in person or via Zoom. Day and evening appointments are available.
Who can participate: Adults ages 18-75 who use prescription opioid medications for chronic pain and do not regularly use cannabis
Contact: Call 617-643-4537 or email potsandmm@mgh.harvard.edu
Treatment of Worry and Anxiety in those with Pain
Conducted By: Boston University
Location: Home-Based
Description: This study is completely online and via mobile device and will last 10-weeks. All participants will receive a digital (online) treatment for anxiety and worry either at the beginning or end of the 10-week period. The study will also involve completing questionnaires on 4 occasions and completing 3 phone calls. Participants can be compensated up to $90 in Amazon giftcards for their time.
Who Can Participate: The study is for adults living in the United States who have persistent muscle or joint pain(>3 months) and have problems with anxiety.
Location: Home-Based
Description: This study is completely online and via mobile device and will last 10-weeks. All participants will receive a digital (online) treatment for anxiety and worry either at the beginning or end of the 10-week period. The study will also involve completing questionnaires on 4 occasions and completing 3 phone calls. Participants can be compensated up to $90 in Amazon giftcards for their time.
Who Can Participate: The study is for adults living in the United States who have persistent muscle or joint pain(>3 months) and have problems with anxiety.
Study Website: sites.bu.edu/painstudy
This study has been approved by Boston University-CRC IRB (protocol number 5975E).
The registered clinical trial ID is NCT04907656.
This study has been approved by Boston University-CRC IRB (protocol number 5975E).
The registered clinical trial ID is NCT04907656.
New Non-Opioid Treatment for Chronic Pain
Knee Osteoarthritis
Study Option 1
The primary objective of this study is to evaluate the safety and efficacy of two doses of CNTX-6970 for the treatment of pain related to OA of the knee compared to placebo. CNTX-6970 is being developed as a new treatment for chronic pain, including painful osteoarthritis of the knee.
The primary objective of this study is to evaluate the safety and efficacy of two doses of CNTX-6970 for the treatment of pain related to OA of the knee compared to placebo. CNTX-6970 is being developed as a new treatment for chronic pain, including painful osteoarthritis of the knee.
Study Option 2
The SKOAP Study is a Sequenced strategy for improving outcomes in people with Knee OsteoArthritis Pain (SKOAP). It is a national study, funded by the Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative®.
SKOAP compares non-opioid pain treatments with the goal of reducing KOA pain and improving function to find out what treatments work best for which patients.
The SKOAP Study is a Sequenced strategy for improving outcomes in people with Knee OsteoArthritis Pain (SKOAP). It is a national study, funded by the Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative®.
SKOAP compares non-opioid pain treatments with the goal of reducing KOA pain and improving function to find out what treatments work best for which patients.
Fibromyalgia
Conducted By: California State University, Fresno (CSUF)
Location: Online Survey
Description:
My name is Thalia Valdez, I’m a Physical Therapy graduate student at California State University, Fresno (CSUF). Under the guidance of Dr. Caio Sarmento, we are conducting a survey on the perceived effectiveness and satisfaction with commonly prescribed treatments for the management of fibromyalgia symptoms. This is an anonymous survey for those 18 and older diagnosed with Fibromyalgia. It will take about 15 minutes to complete. Please follow the link below for more details, and to take the survey. Thank you for your consideration!
Who Can Participate: Those 18 and older diagnosed with Fibromyalgia
Contact: 559-278-2065
Location: Online Survey
Description:
My name is Thalia Valdez, I’m a Physical Therapy graduate student at California State University, Fresno (CSUF). Under the guidance of Dr. Caio Sarmento, we are conducting a survey on the perceived effectiveness and satisfaction with commonly prescribed treatments for the management of fibromyalgia symptoms. This is an anonymous survey for those 18 and older diagnosed with Fibromyalgia. It will take about 15 minutes to complete. Please follow the link below for more details, and to take the survey. Thank you for your consideration!
Who Can Participate: Those 18 and older diagnosed with Fibromyalgia
Contact: 559-278-2065
Healthcare Access: Voices of People with Chronic Pain
Patients tell us they have many problems accessing pain care. Our new study will help us understand these problems better by bringing forward the patient voice. We hope to create a scale to describe the stressors patients with pain face in dealing with the healthcare system. The study process is designed to include patients’ and providers’ voices and experiences, and we hope to hear from you.
For more information about the project and access to study survey, click this link: https://painnews.stanford.edu/news/take-our-healthcare-stress-survey
If you are interested in participating, click this link to see if you qualify: https://redcap.stanford.edu/surveys/?s=7R83RCWXWTXM7C3P
For more information about the project and access to study survey, click this link: https://painnews.stanford.edu/news/take-our-healthcare-stress-survey
If you are interested in participating, click this link to see if you qualify: https://redcap.stanford.edu/surveys/?s=7R83RCWXWTXM7C3P
FDA Digital Health Technology Study for OUD
FDA Study on the Use of Digital Health Technologies for Opioid Use Disorder
FDA is funding a study to learn about how digital health technologies (e.g., apps, programs, or devices that are used for monitoring, tracking, or providing education about health topics) can be used to help people with opioid use disorder (OUD) manage their condition. As part of this study, a researcher from RTI International (www.rti.org) will conduct a focus group with people who have been diagnosed with OUD and are either currently or have recently been in treatment for OUD. The discussion will take place over Zoom, an online video platform and will last 90-minutes. In appreciation of your time,
you will receive a $75 gift card after the discussion.
To see if you qualify, please click the link below to complete a short survey. https://redcapedc.rti.org/ccs/surveys/?s=NEMDXDWL79MTYW3A
If you have any questions, please contact the study team at 877-212-7218 or FDADigitalHealthTechnologies@rti.org.
FDA is funding a study to learn about how digital health technologies (e.g., apps, programs, or devices that are used for monitoring, tracking, or providing education about health topics) can be used to help people with opioid use disorder (OUD) manage their condition. As part of this study, a researcher from RTI International (www.rti.org) will conduct a focus group with people who have been diagnosed with OUD and are either currently or have recently been in treatment for OUD. The discussion will take place over Zoom, an online video platform and will last 90-minutes. In appreciation of your time,
you will receive a $75 gift card after the discussion.
To see if you qualify, please click the link below to complete a short survey. https://redcapedc.rti.org/ccs/surveys/?s=NEMDXDWL79MTYW3A
If you have any questions, please contact the study team at 877-212-7218 or FDADigitalHealthTechnologies@rti.org.
Chronic pain Survey By Aalborg University
If you live with pain, know someone who does, or works as a healthcare professional, we would like to hear what matters to you! 👇
Survey: https://redcap.aau.dk/surveys/?s=FYEMC3K7N7
Our mission is to improve the treatment of chronic pain. As part of this mission, we aim to understand the experience of living with and managing chronic pain from everyone's perspective. By answering the questionnaire, you can help us overcome some of the current uncertainties and challenges in chronic pain management. Your insights will enable us to collaborate closely with patients and patient associations to develop improved care that is meaningful for individuals living with pain, and their families.
You are eligible if you belong to one of the following descriptions:
𝗪𝗵𝗼 𝗮𝗿𝗲 𝘄𝗲?
The project is a collaboration of international researchers, patients, and patient associations. The survey is conducted in collaboration with Aalborg University (AAU) and the Center for General Practice at Aalborg University (CAM AAU). The project is supported by The Danish Rheumatism Association (R222-A8231), and Karen Elise Jensens Foundations. The protocol has been approved by The North Denmark Region Committee on Health Research Ethics. For any questions, please contact Chris Djurtoft (cdjurt@dcm.aau.dk)
Survey: https://redcap.aau.dk/surveys/?s=FYEMC3K7N7
Our mission is to improve the treatment of chronic pain. As part of this mission, we aim to understand the experience of living with and managing chronic pain from everyone's perspective. By answering the questionnaire, you can help us overcome some of the current uncertainties and challenges in chronic pain management. Your insights will enable us to collaborate closely with patients and patient associations to develop improved care that is meaningful for individuals living with pain, and their families.
You are eligible if you belong to one of the following descriptions:
- 𝗣𝗲𝗿𝘀𝗼𝗻 𝗹𝗶𝘃𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗰𝗵𝗿𝗼𝗻𝗶𝗰 𝗽𝗮𝗶𝗻.
- 𝗜𝗻𝗳𝗼𝗿𝗺𝗮𝗹 𝗰𝗮𝗿𝗲𝗴𝗶𝘃𝗲𝗿/𝗿𝗲𝗹𝗮𝘁𝗶𝘃𝗲 to a person living with chronic pain (for instance: a family member or a friend of someone with chronic pain).
- 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗽𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹 working with people living with chronic pain (for instance: medical doctor, physiotherapist, psychologist, occupational therapist, chiropractor).
𝗪𝗵𝗼 𝗮𝗿𝗲 𝘄𝗲?
The project is a collaboration of international researchers, patients, and patient associations. The survey is conducted in collaboration with Aalborg University (AAU) and the Center for General Practice at Aalborg University (CAM AAU). The project is supported by The Danish Rheumatism Association (R222-A8231), and Karen Elise Jensens Foundations. The protocol has been approved by The North Denmark Region Committee on Health Research Ethics. For any questions, please contact Chris Djurtoft (cdjurt@dcm.aau.dk)